title: Effect of erythropoietin therapy on the progression of cisplatin induced renal injury in rats.
abstract: Cisplatin is one of the most important chemotherapeutic agents useful in the treatment of a variety of solid tumors; however, it has several side effects such as nephrotoxicity. In the present study, the effect of rhEPO on acute kidney injury induced by i.p. injection of rats with 9.0 mg/kg cisplatin was studied. It was observed that EPO treated group showed a significantly lower rate in the extent and severity of the histological signs of kidney injury than untreated one. This is attributed to (i) a decrease in the elevated oxidative and nitrosative stress markers, (ii) reduction of the expression of VEGF, HO-1 and iNOS as well as (iii) improvement of Bcl2 immunoreaction in most tubular cells. Thus, EPO may be one of the futures therapeutic possibilities to overcome the side effects of anti-cancer drugs induced acute renal injury through various mechanisms including down regulation of vascular endothelial growth factor (VEGF), hemeoxygenase-1 (HO-1) and inducible nitric oxide synthase (iNOS) expressions in addition to stimulation of tubular cell regeneration.
authors.affiliation: Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Sharkia Gov., Zagazig 44519, Egypt.
authors.forename: Hoda E
authors.initials: HE
authors.lastname: Mohamed
authors.forename: Sahar E
authors.initials: SE
authors.lastname: El-Swefy
authors.forename: Rasha H
authors.initials: RH
authors.lastname: Mohamed
authors.forename: Amal M H
authors.initials: AM
authors.lastname: Ghanim
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D001772:Blood Cell Count; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity*; D018450:Disease Progression; D004587:Electrophoresis, Agar Gel; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D015870:Gene Expression / Q000187:drug effects; D007677:Kidney Function Tests; D008297:Male; D052247:Nitric Oxide Synthase Type II / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D020133:Reverse Transcriptase Polymerase Chain Reaction; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C554270:EPO protein, human; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D004921:Erythropoietin; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D002945:Cisplatin